New data on Nemluvio® (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo nodularis from the phase III OLYMPIA program, and post-hoc analyses exploring the continuous response of Nemluvio up to 56 weeks in atopic dermatitis patients from the ARCADIA 1&2 trials and long-term extension study […]
Galderma will present 22 e-posters, including two oral presentations, at the 2025 American Academy of Dermatology (AAD) Annual Meeting, showcasing updates on its dermatology portfolio. Key highlights include new data on Nemluvio (nemolizumab) for prurigo nodularis and atopic dermatitis, Relfydess (RelabotulinumtoxinA) for frown lines and crow’s feet, and advancements in Restylane and Sculptra for aesthetic treatments. Additionally, the company will present updates on its acne and sensitive skin product portfolio. These presentations underscore Galderma’s position as a category leader in dermatology with a strong, innovative pipeline. The company will also host an Industry Session Theatre on targeting the IL-31 neuroimmune pathway. AAD attendees can explore Galderma’s presentations at booth #2021.
